Abbott: Colitis trials

The registry lists 11 Colitis studies with Abbott as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 1Phase 2 7Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT00408629Phase 3Results posted
• Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative ColitisCompletedNCT00385736Phase 3Results posted
• Infants With Protein Sensitive ColitisCompletedNCT01813526Not applicable
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisWithdrawnNCT00502294Phase 3
• Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)TerminatedNCT00307827Phase 2
• Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyTerminatedNCT00279435Phase 2/3
• A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisTerminatedNCT00279422Phase 2/3
• Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative ColitisCompletedNCT00267306Phase 1/2
• Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative ColitisCompletedNCT00073047Phase 2
• A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's DiseaseCompletedNCT00072943Phase 2
• Research Study in Patients With Severe Ulcerative ColitisCompletedNCT00032305Phase 2/3